Index RUT P/E - EPS (ttm) -3.92 Insider Own 0.60% Shs Outstand 21.48M Perf Week -7.25%
Market Cap 1.12B Forward P/E - EPS next Y -4.49 Insider Trans -93.86% Shs Float 18.72M Perf Month -10.83%
Income -63.20M PEG - EPS next Q -0.80 Inst Own 85.10% Short Float / Ratio 2.68% / 2.16 Perf Quarter -9.66%
Sales - P/S - EPS this Y 84.90% Inst Trans 4.46% Short Interest 0.50M Perf Half Y 126.54%
Book/sh 17.28 P/B 2.84 EPS next Y -27.60% ROA -27.10% Target Price 67.11 Perf Year 233.33%
Cash/sh 16.56 P/C 2.96 EPS next 5Y - ROE -28.60% 52W Range 11.80 - 57.70 Perf YTD 146.35%
Dividend - P/FCF - EPS past 5Y - ROI - 52W High -15.08% Beta -0.05
Dividend % - Quick Ratio 39.40 Sales past 5Y - Gross Margin - 52W Low 315.25% ATR 2.69
Employees 46 Current Ratio 39.40 Sales Q/Q - Oper. Margin - RSI (14) 39.75 Volatility 5.61% 5.03%
Optionable Yes Debt/Eq 0.00 EPS Q/Q 54.70% Profit Margin - Rel Volume 0.58 Prev Close 48.98
Shortable Yes LT Debt/Eq 0.00 Earnings Aug 11 BMO Payout - Avg Volume 232.11K Price 49.00
Recom 1.60 SMA20 -8.40% SMA50 -3.68% SMA200 45.94% Volume 133,571 Change 0.04%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-09-23 Upgrade Raymond James
Outperform → Strong Buy
$50 → $75
Jun-07-23 Initiated H.C. Wainwright
Buy
$55
May-17-23 Initiated Raymond James
Outperform
$50
Apr-28-23 Initiated Cantor Fitzgerald
Overweight
$45
Apr-21-23 Initiated Stifel
Buy
$37
Apr-20-23 Initiated Morgan Stanley
Overweight
$37
Mar-23-23 Initiated BMO Capital Markets
Outperform
$40
Feb-28-23 Initiated SVB Securities
Outperform
$36
Sep-20-23 04:30PM
Aug-30-23 04:15PM
Aug-24-23 11:20AM
(Investor's Business Daily)
Aug-11-23 08:50AM
08:00AM
09:00AM
Loading…
Jul-27-23 09:00AM
Jul-25-23 09:55AM
Jun-22-23 04:15PM
Jun-20-23 07:33PM
Jun-13-23 10:39PM
Jun-12-23 04:00PM
01:59AM
Jun-09-23 04:13PM
(Investor's Business Daily) +15.76%
07:00AM
Jun-01-23 03:10PM
04:00PM
Loading…
May-31-23 04:00PM
May-15-23 07:00AM
May-11-23 10:15AM
May-10-23 10:23AM
May-05-23 08:50AM
May-04-23 12:00PM
Apr-28-23 05:00AM
Apr-27-23 08:05AM
Apr-21-23 08:30AM
Apr-19-23 08:50AM
Apr-13-23 11:00AM
Mar-31-23 07:00AM
Mar-30-23 07:05AM
Mar-21-23 07:00AM
Feb-16-23 08:00AM
06:30AM
Loading…
Feb-14-23 06:30AM
Feb-08-23 04:00PM
Jan-20-23 07:00AM
Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Atlas Venture Fund X, L.P. 10% Owner Sep 16 Sale 53.22 2,115 112,560 1,593,785 Sep 18 04:59 PM Atlas Venture Fund X, L.P. 10% Owner Sep 15 Sale 53.16 260,894 13,869,125 1,595,900 Sep 18 04:59 PM Atlas Venture Fund X, L.P. 10% Owner Sep 14 Sale 53.05 94,440 5,010,042 1,856,794 Sep 18 04:59 PM Bryce Joanne Chief Financial Officer Sep 11 Option Exercise 9.86 2,500 24,650 3,760 Sep 13 04:15 PM Bryce Joanne Chief Financial Officer Sep 01 Option Exercise 2.65 1,000 2,650 2,260 Sep 05 04:16 PM Bryce Joanne Chief Financial Officer Sep 01 Sale 52.99 1,000 52,990 1,260 Sep 05 04:16 PM Savage William Jacob Chief Medical Officer Aug 21 Option Exercise 2.65 3,000 7,950 3,000 Aug 22 04:06 PM Atlas Venture Fund X, L.P. 10% Owner Aug 15 Sale 52.40 111,069 5,820,016 1,951,234 Aug 16 06:55 PM Bitterman Kevin Director Aug 15 Sale 52.40 72,931 3,821,584 882,224 Aug 17 04:13 PM Atlas Venture Fund X, L.P. 10% Owner Aug 15 Sale 52.40 72,931 3,821,584 882,224 Aug 16 06:55 PM Savage William Jacob Chief Medical Officer Aug 15 Sale 52.95 7,672 406,235 0 Aug 16 04:15 PM Atlas Venture Fund X, L.P. 10% Owner Aug 14 Sale 52.59 175,000 9,203,600 2,062,303 Aug 16 06:55 PM Savage William Jacob Chief Medical Officer Aug 09 Sale 49.83 8,269 412,064 7,672 Aug 11 04:15 PM Bryce Joanne Chief Financial Officer Aug 01 Option Exercise 1.01 4,521 4,566 5,781 Aug 03 04:18 PM Bryce Joanne Chief Financial Officer Aug 01 Sale 49.91 4,521 225,633 1,260 Aug 03 04:18 PM MacDonald Brian Richard Chief Innovation Officer Jun 30 Sale 45.05 4,324 194,778 12,876 Jun 30 06:29 PM MacDonald Brian Richard Chief Innovation Officer Jun 29 Sale 45.79 5,100 233,509 17,200 Jun 30 06:29 PM Bryce Joanne Chief Financial Officer Jun 28 Option Exercise 1.01 7,880 7,959 11,332 Jun 30 04:49 PM Novo Holdings A/S 10% Owner Jun 28 Sale 46.10 1,250,000 57,625,000 1,090,772 Jun 28 05:04 PM Bryce Joanne Chief Financial Officer Jun 28 Sale 49.95 10,072 503,114 1,260 Jun 30 04:49 PM MacDonald Brian Richard Chief Innovation Officer Jun 28 Sale 49.96 5,100 254,795 22,300 Jun 30 06:29 PM Savage William Jacob Chief Medical Officer Jun 28 Sale 49.98 4,384 219,114 15,941 Jun 30 04:12 PM AI DMI LLC 10% Owner Feb 15 Buy 23.00 434,783 10,000,009 3,141,759 Feb 17 04:42 PM Ashiya Mona Director Feb 15 Buy 23.00 108,696 2,500,008 1,196,825 Feb 17 04:48 PM ORBIMED ADVISORS LLC Director Feb 15 Buy 23.00 108,696 2,500,008 1,196,825 Feb 17 04:43 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
